EyePoint Pharmaceuticals Poised for Growth With Promising DME Treatment Duravyu

TipRanks17:05 ET

Some EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shareholders Look For Exit As Shares Take 27% Pounding

Simply Wall StDec 1 07:12 ET

Selling EyePoint Pharmaceuticals Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders

Simply Wall StNov 21 06:38 ET

Express News | EyePoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

ReutersNov 18 07:00 ET

Wall Street Analysts See a 175.07% Upside in EyePoint Pharmaceuticals (EYPT): Can the Stock Really Move This High?

Yahoo FinanceNov 13 09:55 ET

Baird Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Cuts Target Price to $33

Moomoo NewsNov 11 07:31 ET · Ratings